Search results for "Venous thromboembolism"
Patients with provoked VTE often on anticoagulation longer than recommended
Three variables were associated with receiving anticoagulation for longer than three months after a provoked venous thromboembolism (VTE): direct oral anticoagulant use, history of VTE, and history of myocardial infarction.
https://immattersacp.org/weekly/archives/2022/11/01/4.htm
1 Nov 2022
Apixaban shows superior effectiveness, safety compared to rivaroxaban
For patients with venous thromboembolism, initiation of apixaban was associated with lower rates of recurrence and intracranial and gastrointestinal bleeding than rivaroxaban in a population-based cohort study.
https://immattersacp.org/weekly/archives/2021/12/07/2.htm
7 Dec 2021
DOACs may be safe, effective for VTE prevention in patients with higher weight, BMI
Patients with first-time venous thromboembolism (VTE) who weighed 120 kg or more and had a body mass index (BMI) of 40 kg/m2 or more were not at higher risk for bleeding or recurrent VTE with direct-acting oral anticoagulants (DOACs) versus warfarin.
https://immattersacp.org/weekly/archives/2021/11/09/4.htm
9 Nov 2021
Long-term anticoagulation after first unprovoked VTE associated with considerable bleeding risk
Results from a systematic review and meta-analysis provide a framework for clinicians and patients to balance the benefits and harms of extended anticoagulation for unprovoked venous thromboembolism (VTE).
https://immattersacp.org/weekly/archives/2021/09/14/4.htm
14 Sep 2021
Guidelines offer 28 recommendations for initial management, secondary prevention of DVT and PE
Among other recommendations, the new guidelines from the American Society of Hematology suggest offering home treatment to low-risk patients with deep venous thrombosis (DVT) or pulmonary embolism (PE).
https://immattersacp.org/weekly/archives/2020/10/20/5.htm
20 Oct 2020
Industry-funded trial finds a direct factor X inhibitor noninferior to a low-molecular-weight heparin for cancer-associated VTE
Edoxaban was associated with a lower rate of recurrent venous thromboembolism (VTE) but a higher rate of major bleeding.
https://immattersacp.org/weekly/archives/2017/12/19/2.htm
19 Dec 2017
Major bleeding, mortality risks after VTE similar on DOACs or warfarin
The risk of major bleeding and of death was similar for patients taking direct oral anticoagulants compared to those taking warfarin.
https://immattersacp.org/weekly/archives/2017/10/24/4.htm
24 Oct 2017
Outcomes of limited cancer screening after unprovoked VTE similar to extensive screening
The overall prevalence of cancer in the 12 months after a diagnosis of venous thromboembolism was 5.2%. While the point prevalence was higher in patients receiving extensive screening than in those receiving limited screening, there was no significant difference at one year.
https://immattersacp.org/weekly/archives/2017/08/22/4.htm
22 Aug 2017
Low-molecular-weight heparin may not prevent VTE after knee arthroscopy or lower-leg casting, studies find
The Prevention of Thrombosis after Knee Arthroscopy (POT-KAST) and the Prevention of Thrombosis after Lower Leg Plaster Cast (POT-CAST) trials used the same methods and design to compare a prophylactic dose of low-molecular-weight heparin or no anticoagulant therapy.
https://immattersacp.org/weekly/archives/2016/12/13/4.htm
13 Dec 2016
NSAID use may be associated with increased VTE risk
There may be a statistically significant increased risk of venous thromboembolism (VTE) among users of nonsteroidal anti-inflammatory drugs (NSAIDs), a meta-analysis found.
https://immattersacp.org/weekly/archives/2014/09/30/4.htm
30 Sep 2014
Systematic review compares new and old anticoagulation options for acute VTE
The benefits and risks of 8 different anticoagulation strategies for patients with venous thromboembolism (VTE), including heparin and new oral anticoagulants, were compared in a large new analysis.
https://immattersacp.org/weekly/archives/2014/09/23/7.htm
23 Sep 2014
Aspirin may be noninferior to dalteparin for VTE prophylaxis following hip replacements
Aspirin therapy for 28 days may be a reasonable alternative to low-molecular-weight heparin for extended venous thromboembolism (VTE) prophylaxis among hip replacement patients who have already received low-molecular-weight heparin for 10 days, a study found.
https://immattersacp.org/weekly/archives/2013/06/04/5.htm
4 Jun 2013
Aspirin appears to reduce recurrence of VTE after stopping anticoagulants
Aspirin reduced the risk of venous thromboembolism (VTE) recurrence with no apparent increase in major bleeding in patients who had an initial unprovoked VTE and had discontinued anticoagulant treatment, a study found.
https://immattersacp.org/weekly/archives/2012/06/05/6.htm
5 Jun 2012
Fixed-dose oral rivaroxaban appears noninferior to standard therapy for PE
Fixed-dose oral rivaroxaban is as effective as standard anticoagulant therapy for pulmonary embolism (PE) and may have a lower bleeding risk, a new study found.
https://immattersacp.org/weekly/archives/2012/03/27/5.htm
27 Mar 2012
New model predicts future risk of VTE
Researchers have devised a new algorithm to predict a patient's risk of developing venous thromboembolism in the next five years, based on simple clinical variables.
https://immattersacp.org/weekly/archives/2011/08/23/4.htm
23 Aug 2011